BIO taps Global Blood Therapeutics' Ted Love as board chair

By Rachel Cohrs June 5, 2023

WASHINGTON — Ted Love has pretty much done everything there is to do in biotech.

He's worked for tiny startups and mega corporations. He sold his latest company to Pfizer for $5 billion amid an industry downturn. And now, he's taking on a new challenge by becoming the chair of the board of the largest biotechnology lobby, BIO.

advertisement

He hopes to use his experience across the drug development process to improve the biotech industry's reputation in Washington, following a bruising lobbying fight the industry lost when Democrats gave Medicare the power to negotiate drug prices, and the organization's messy separation from its former CEO last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Washington Correspondent

Rachel Cohrs reports on the intersection of politics and health policy.

advocacy

biotechnology

Congress

life sciences

pharmaceuticals

policy

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.